# 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.

> **NCT02088645** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 24 (estimated)

## Conditions studied

- Thyroid Cancer, Medullary
- Neuroendocrine Tumor of the Lung Grade 1 and 2
- Neuroendocrine Tumor of the Thymus Grade 1 and 2
- Neuroendocrine Tumor GEP Grade 1-3

## Interventions

- **DRUG:** 177Lu-PP-F11N

## Key facts

- **NCT ID:** NCT02088645
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-04
- **Primary completion:** 2027-04
- **Final completion:** 2028-04
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02088645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02088645, "177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02088645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*